Concepts (198)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 42 | 2023 | 955 | 10.710 |
Why?
|
| Exercise | 11 | 2023 | 315 | 3.210 |
Why?
|
| Telemedicine | 3 | 2022 | 169 | 1.940 |
Why?
|
| Sports | 2 | 2022 | 39 | 1.630 |
Why?
|
| Quality of Life | 8 | 2022 | 1585 | 1.390 |
Why?
|
| Pandemics | 6 | 2022 | 740 | 1.380 |
Why?
|
| Betacoronavirus | 3 | 2020 | 258 | 1.320 |
Why?
|
| Eosinophilia | 2 | 2019 | 84 | 1.230 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 316 | 1.150 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 301 | 1.150 |
Why?
|
| Rhinitis | 3 | 2021 | 175 | 1.040 |
Why?
|
| Sleep Apnea, Obstructive | 4 | 2020 | 219 | 0.960 |
Why?
|
| Hypersensitivity | 2 | 2022 | 154 | 0.940 |
Why?
|
| Humans | 58 | 2023 | 86644 | 0.880 |
Why?
|
| Gastroesophageal Reflux | 2 | 2022 | 117 | 0.820 |
Why?
|
| Anti-Asthmatic Agents | 4 | 2019 | 76 | 0.810 |
Why?
|
| Fitness Trackers | 1 | 2021 | 5 | 0.790 |
Why?
|
| Social Determinants of Health | 1 | 2022 | 78 | 0.790 |
Why?
|
| Disease Management | 1 | 2023 | 327 | 0.780 |
Why?
|
| Comparative Effectiveness Research | 2 | 2018 | 53 | 0.740 |
Why?
|
| Telemetry | 1 | 2020 | 38 | 0.730 |
Why?
|
| Wearable Electronic Devices | 1 | 2020 | 23 | 0.730 |
Why?
|
| Healthy Lifestyle | 1 | 2020 | 9 | 0.730 |
Why?
|
| Physical Fitness | 1 | 2020 | 51 | 0.720 |
Why?
|
| Self-Management | 2 | 2019 | 29 | 0.710 |
Why?
|
| Lysophospholipase | 1 | 2019 | 3 | 0.710 |
Why?
|
| Galectins | 1 | 2019 | 9 | 0.700 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 98 | 0.690 |
Why?
|
| Natural Language Processing | 1 | 2019 | 37 | 0.670 |
Why?
|
| Self Care | 2 | 2019 | 164 | 0.660 |
Why?
|
| Glycoproteins | 1 | 2019 | 234 | 0.630 |
Why?
|
| Adult | 24 | 2023 | 25648 | 0.610 |
Why?
|
| Social Media | 1 | 2019 | 79 | 0.610 |
Why?
|
| Depression | 1 | 2020 | 473 | 0.590 |
Why?
|
| Lung | 3 | 2022 | 1170 | 0.590 |
Why?
|
| Comorbidity | 5 | 2020 | 943 | 0.570 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 238 | 0.570 |
Why?
|
| Obesity | 2 | 2020 | 963 | 0.550 |
Why?
|
| Sinusitis | 3 | 2022 | 210 | 0.540 |
Why?
|
| Inflammation | 4 | 2019 | 920 | 0.540 |
Why?
|
| Spirometry | 4 | 2023 | 66 | 0.530 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2015 | 23 | 0.520 |
Why?
|
| Child | 12 | 2023 | 6927 | 0.520 |
Why?
|
| Life Style | 3 | 2021 | 189 | 0.520 |
Why?
|
| Allergens | 5 | 2021 | 179 | 0.500 |
Why?
|
| Research Design | 1 | 2018 | 594 | 0.480 |
Why?
|
| Neutrophils | 2 | 2017 | 307 | 0.460 |
Why?
|
| Clinical Trials as Topic | 2 | 2018 | 1169 | 0.450 |
Why?
|
| Glucocorticoids | 1 | 2015 | 352 | 0.440 |
Why?
|
| Vulnerable Populations | 2 | 2023 | 76 | 0.420 |
Why?
|
| Rhinitis, Allergic | 2 | 2022 | 43 | 0.400 |
Why?
|
| Middle Aged | 14 | 2023 | 25028 | 0.390 |
Why?
|
| Aged | 10 | 2022 | 18415 | 0.380 |
Why?
|
| Emergency Service, Hospital | 4 | 2022 | 484 | 0.360 |
Why?
|
| Respiratory System | 1 | 2010 | 116 | 0.350 |
Why?
|
| Delivery of Health Care | 3 | 2023 | 426 | 0.350 |
Why?
|
| Young Adult | 8 | 2021 | 5976 | 0.340 |
Why?
|
| Sputum | 2 | 2019 | 34 | 0.320 |
Why?
|
| Feasibility Studies | 2 | 2021 | 751 | 0.320 |
Why?
|
| Public Health | 2 | 2020 | 129 | 0.320 |
Why?
|
| Adolescent | 7 | 2023 | 8981 | 0.320 |
Why?
|
| Desensitization, Immunologic | 2 | 2019 | 36 | 0.310 |
Why?
|
| Age Factors | 4 | 2019 | 1851 | 0.310 |
Why?
|
| Weight Loss | 2 | 2020 | 229 | 0.300 |
Why?
|
| Neoplasms | 1 | 2022 | 2898 | 0.290 |
Why?
|
| United States | 9 | 2023 | 6672 | 0.290 |
Why?
|
| Female | 18 | 2023 | 44533 | 0.280 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2023 | 247 | 0.270 |
Why?
|
| Male | 17 | 2023 | 40966 | 0.250 |
Why?
|
| Lysophospholipids | 2 | 2016 | 63 | 0.250 |
Why?
|
| Surveys and Questionnaires | 2 | 2022 | 2501 | 0.240 |
Why?
|
| Food Supply | 1 | 2023 | 28 | 0.230 |
Why?
|
| Climate Change | 1 | 2023 | 42 | 0.220 |
Why?
|
| Paranasal Sinus Diseases | 1 | 2022 | 25 | 0.220 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 1621 | 0.220 |
Why?
|
| Exhalation | 1 | 2022 | 7 | 0.220 |
Why?
|
| Breath Tests | 1 | 2022 | 55 | 0.210 |
Why?
|
| Policy | 1 | 2022 | 34 | 0.210 |
Why?
|
| Anxiety | 2 | 2022 | 287 | 0.210 |
Why?
|
| Prevalence | 3 | 2023 | 1239 | 0.210 |
Why?
|
| Life Change Events | 1 | 2022 | 48 | 0.210 |
Why?
|
| Evidence-Based Practice | 2 | 2019 | 45 | 0.210 |
Why?
|
| Air Pollution | 1 | 2022 | 68 | 0.210 |
Why?
|
| Masks | 1 | 2021 | 29 | 0.200 |
Why?
|
| Disinfectants | 1 | 2020 | 8 | 0.200 |
Why?
|
| Environmental Pollutants | 1 | 2021 | 51 | 0.200 |
Why?
|
| Forced Expiratory Volume | 2 | 2022 | 122 | 0.200 |
Why?
|
| Self Report | 2 | 2019 | 288 | 0.190 |
Why?
|
| Counseling | 1 | 2022 | 145 | 0.190 |
Why?
|
| Nitric Oxide | 1 | 2022 | 278 | 0.190 |
Why?
|
| Chronic Disease | 2 | 2022 | 971 | 0.180 |
Why?
|
| Patient Outcome Assessment | 2 | 2017 | 84 | 0.180 |
Why?
|
| Lung Diseases | 1 | 2022 | 263 | 0.180 |
Why?
|
| Phenotype | 3 | 2017 | 2378 | 0.180 |
Why?
|
| Data Collection | 1 | 2021 | 372 | 0.180 |
Why?
|
| Observer Variation | 2 | 2018 | 602 | 0.170 |
Why?
|
| Polypharmacy | 1 | 2019 | 15 | 0.170 |
Why?
|
| Respiratory Sounds | 1 | 2018 | 33 | 0.170 |
Why?
|
| Airway Remodeling | 2 | 2016 | 9 | 0.170 |
Why?
|
| Patient Education as Topic | 2 | 2019 | 351 | 0.170 |
Why?
|
| Mexican Americans | 1 | 2018 | 63 | 0.170 |
Why?
|
| Biomedical Research | 1 | 2023 | 376 | 0.170 |
Why?
|
| Cough | 1 | 2018 | 54 | 0.170 |
Why?
|
| Health Promotion | 1 | 2020 | 160 | 0.160 |
Why?
|
| Eosinophils | 1 | 2019 | 194 | 0.160 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 2016 | 121 | 0.160 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2018 | 50 | 0.160 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2019 | 376 | 0.160 |
Why?
|
| Health Behavior | 1 | 2019 | 183 | 0.150 |
Why?
|
| Phosphoric Diester Hydrolases | 2 | 2016 | 25 | 0.150 |
Why?
|
| Residence Characteristics | 1 | 2018 | 197 | 0.150 |
Why?
|
| Income | 1 | 2017 | 75 | 0.150 |
Why?
|
| Rifampin | 1 | 2016 | 22 | 0.150 |
Why?
|
| Drug Hypersensitivity | 1 | 2016 | 37 | 0.140 |
Why?
|
| Leukocyte Count | 1 | 2017 | 220 | 0.140 |
Why?
|
| Anaphylaxis | 1 | 2016 | 33 | 0.140 |
Why?
|
| Pilot Projects | 1 | 2019 | 839 | 0.140 |
Why?
|
| Immunoglobulin E | 1 | 2017 | 144 | 0.140 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 160 | 0.140 |
Why?
|
| Precision Medicine | 1 | 2020 | 395 | 0.140 |
Why?
|
| Circadian Rhythm | 1 | 2018 | 303 | 0.140 |
Why?
|
| Patient Transfer | 1 | 2016 | 91 | 0.140 |
Why?
|
| Registries | 1 | 2019 | 702 | 0.140 |
Why?
|
| Complementary Therapies | 1 | 2016 | 54 | 0.130 |
Why?
|
| Biomarkers | 2 | 2019 | 1718 | 0.130 |
Why?
|
| Chemokine CCL2 | 1 | 2015 | 47 | 0.130 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2017 | 263 | 0.130 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 429 | 0.130 |
Why?
|
| Tuberculosis | 1 | 2016 | 110 | 0.130 |
Why?
|
| Macrophages, Alveolar | 1 | 2015 | 55 | 0.130 |
Why?
|
| Case-Control Studies | 1 | 2019 | 1805 | 0.120 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 2705 | 0.120 |
Why?
|
| Sleep | 1 | 2018 | 444 | 0.120 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 199 | 0.120 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2016 | 186 | 0.120 |
Why?
|
| Disease Progression | 1 | 2019 | 1531 | 0.120 |
Why?
|
| Electronic Health Records | 1 | 2017 | 319 | 0.120 |
Why?
|
| Patient Selection | 1 | 2017 | 685 | 0.120 |
Why?
|
| Aged, 80 and over | 3 | 2017 | 6509 | 0.120 |
Why?
|
| Risk Factors | 6 | 2020 | 5417 | 0.110 |
Why?
|
| DNA-Binding Proteins | 1 | 2019 | 1208 | 0.110 |
Why?
|
| Blood Pressure | 1 | 2018 | 1143 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 1036 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 746 | 0.100 |
Why?
|
| Treatment Outcome | 2 | 2020 | 7993 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 2271 | 0.090 |
Why?
|
| Chicago | 3 | 2018 | 1379 | 0.080 |
Why?
|
| Animals | 5 | 2020 | 26582 | 0.080 |
Why?
|
| Aging | 1 | 2013 | 691 | 0.080 |
Why?
|
| Hospitalization | 1 | 2014 | 849 | 0.080 |
Why?
|
| Socioeconomic Factors | 2 | 2020 | 567 | 0.070 |
Why?
|
| Odds Ratio | 2 | 2018 | 678 | 0.070 |
Why?
|
| Housing | 1 | 2023 | 42 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2022 | 8489 | 0.060 |
Why?
|
| Particulate Matter | 1 | 2022 | 79 | 0.050 |
Why?
|
| Ecological Momentary Assessment | 1 | 2022 | 25 | 0.050 |
Why?
|
| Demography | 1 | 2022 | 177 | 0.050 |
Why?
|
| Respiratory Function Tests | 1 | 2022 | 136 | 0.050 |
Why?
|
| Satellite Imagery | 1 | 2018 | 3 | 0.040 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2018 | 23 | 0.040 |
Why?
|
| Information Systems | 1 | 2018 | 29 | 0.040 |
Why?
|
| Actigraphy | 1 | 2018 | 51 | 0.040 |
Why?
|
| Plants | 1 | 2018 | 112 | 0.040 |
Why?
|
| Health Information Exchange | 1 | 2017 | 12 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2016 | 2232 | 0.040 |
Why?
|
| Urban Population | 1 | 2018 | 213 | 0.040 |
Why?
|
| Heart | 1 | 2020 | 539 | 0.040 |
Why?
|
| Cooperative Behavior | 1 | 2017 | 174 | 0.040 |
Why?
|
| Environmental Exposure | 1 | 2018 | 296 | 0.040 |
Why?
|
| Phospholipases A1 | 1 | 2016 | 1 | 0.040 |
Why?
|
| Receptors, Lysophosphatidic Acid | 1 | 2016 | 14 | 0.030 |
Why?
|
| Lysophosphatidylcholines | 1 | 2016 | 18 | 0.030 |
Why?
|
| Antigens, Dermatophagoides | 1 | 2015 | 11 | 0.030 |
Why?
|
| Pyroglyphidae | 1 | 2015 | 14 | 0.030 |
Why?
|
| Chemotaxis | 1 | 2015 | 72 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 684 | 0.030 |
Why?
|
| Pregnancy | 1 | 2022 | 2894 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2015 | 319 | 0.030 |
Why?
|
| Caregivers | 1 | 2015 | 151 | 0.030 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2014 | 21 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2022 | 4214 | 0.030 |
Why?
|
| Incidence | 1 | 2018 | 1577 | 0.030 |
Why?
|
| Population Groups | 1 | 2014 | 41 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2016 | 339 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2017 | 428 | 0.030 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2013 | 53 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2017 | 1823 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 3640 | 0.030 |
Why?
|
| Mice | 2 | 2016 | 11352 | 0.020 |
Why?
|
| Transcriptome | 1 | 2015 | 580 | 0.020 |
Why?
|
| Cell Line | 1 | 2015 | 2468 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2018 | 2261 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2017 | 3612 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 1540 | 0.020 |
Why?
|
| Time Factors | 1 | 2018 | 5210 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 3092 | 0.020 |
Why?
|
| Physicians | 1 | 2015 | 673 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2013 | 3241 | 0.010 |
Why?
|